XML 52 R41.htm IDEA: XBRL DOCUMENT v3.21.1
Asset Acquisitions - Additional Information (Details)
1 Months Ended 3 Months Ended
Dec. 31, 2020
USD ($)
Jul. 31, 2019
USD ($)
Nov. 30, 2018
USD ($)
ProductCandidate
$ / shares
shares
Mar. 31, 2021
USD ($)
Asset Acquisitions [Line Items]        
Accrued milestones       $ 15,000,000
Shire Agreement | Shire        
Asset Acquisitions [Line Items]        
Number of product candidates | ProductCandidate     2  
Upfront payment     $ 7,500,000  
Product sales milestone payments, payable     30,000,000  
Milestone payment   $ 2,500,000    
Milestone payments, upon clinical trial treatment       2,000,000
Accrued milestones       15,000,000
Shire Agreement | Shire | Maralixibat        
Asset Acquisitions [Line Items]        
Milestone payments, payable     109,500,000  
Milestone payments, payable upon approval     25,000,000  
Milestone payment $ 10,000,000      
Accrued milestones       10,000,000
Shire Agreement | Shire | Volixibat        
Asset Acquisitions [Line Items]        
Milestone payments, payable     $ 30,000,000  
Shire Agreement | Shire | Clinical Trial in ALGS        
Asset Acquisitions [Line Items]        
Accrued milestones       5,000,000
Shire Agreement | Shire | Redeemable Common Stock        
Asset Acquisitions [Line Items]        
Temporary equity, shares issued | shares     1,859,151  
Issuance of Series A redeemable convertible preferred stock, net of issuance costs     $ 7,000,000  
Shares issued, price per share | $ / shares     $ 3.76  
Assigned License Agreement | Satiogen Pharmaceuticals, Inc.        
Asset Acquisitions [Line Items]        
Milestone payments, payable     $ 10,500,000  
Milestone payments, payable upon approval     5,000,000  
Accrued milestones       0
Milestone payments, payable upon initiation     500,000  
Milestone payments, payable upon commercialization     5,000,000  
Assigned License Agreement | Sanofi-Aventis Deutschland GmbH        
Asset Acquisitions [Line Items]        
Milestone payments, payable     $ 36,000,000  
Royalty obligations payment period     10 years  
Milestones accrued       $ 0
Assigned License Agreement | Maralixibat | Satiogen Pharmaceuticals, Inc.        
Asset Acquisitions [Line Items]        
Milestone payment   $ 500,000